L20
Conditions
Interventions
Group 1: arm 1: patients with chronic-inflammatory skin diseases with chronic pruritus.
The main goal of the proposed project is to thoroughly characterize known (IL-31/IL-31RA) and identify novel it
B, anti-IL-4RA/duppilumab
C, JAK1/2 inhibition/baricitinib). AD patients (n=15/intervention) will be clinically characterized, undergo optimized electrical stimulation protocols, and have skin surface biopsies (cyanoacrylate a
the day after the start of the intervention (d1), one week (d7), and one month (d30). A matched cohort of healthy volunteers
Sponsors
Universitätsklinik für Dermatologie und Allergologie, Klinikum Oldenburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with chronic pruritus (due to lichen planus, psoriasis and atopic dermatitis); minimum age 18 years
Exclusion criteria
Exclusion criteria: Patients who cannot complete the questionnaires due to physical or psychiatric diseases or an insufficient understanding of the German language. Patients taking antipruritic drugs. Patients with an infection at the potential biopsy area. Patients who received anti-inflammatory therapy within the last two weeks and pregnant or breast-feeding women are excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Microbiome characterization of skin at each time point of intervention (d0, 1, 7, 30); expression profiles of pruritic mediators (immunohistochemical and immunofluorescence staining, ELISA, Western blots, Luminex). Gene expression profiles (qPCR, RNA sequencing), Patient questionnaires (d0, 1, 7, 30): NeuroDerm questionnaire, 5PLQ, SF12, Beck Depression Inventory (BDI), STAI-T (State-Trait Anxiety Inventory), SCQ (Self-Administered Comorbidity Questionnaire), BPI (Brief Pain Inventory), Pain Catastrophizing Scale, NPSI (Neuropathich pain symptom inventory). | — |
Secondary
| Measure | Time frame |
|---|---|
| Findings of this study will increase our understanding of molecular and cellular pathways inducing pruritus with an emphasis on understanding the role of IL-31RA signaling, will define and validate biomarkers for chronic pruritus and potentially identify disease-specific biomarkers, will characterize known therapeutic targets for the treatment of chronic pruritus and identify future therapeutic perspectives and will unravel the role of microbes as exogenous triggers of itch. | — |
Countries
Germany
Contacts
Public ContactMaren Limberg
Universitätsklinik für Dermatologie und Allergologie, Klinikum Oldenburg
Outcome results
None listed